Erratum to: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study

Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone and Aripiprazole in Table Ten.

Following the publication of our article [1], it has come to our attention that there was an error with the values listed for Ziprasidone and Aripiprazole in Table Ten. Table Ten should therefore appear as shown in this correction (Table 1).

Affiliations

1. Department of Economics, University of Thessaly, Magnissias 96, Dionyssos, 14576, Greece

   • Maria Geitona

2. Institute for Economic and Industrial Research, Tsami Karatasi 11, 117 42, Athens, Greece

   • Hara Kousoulakou

3. Department of Health Economics, National School of Public Health, Aleksandra's Avenue 196, 11521, Athens, Greece

   • Markos Ollandezos
   • , Kostas Athanasakis
   •  & Ioannis Kyriopoulos

4. Janssen-Cilag Pharmaceutical SACI, Eirinis Avenue 56, 15121, Pefki, Athens, Greece

   • Sotiria Papanicolaou

Corresponding author

Correspondence to Sotiria Papanicolaou.

The online version of the original article can be found at 10.1186/1744-859X-7-16

Reprints and Permissions